Search

Objective: To study the characteristics of platelet rich plasma(PRP) in the treatment of lower limb skin defect and to find out the most suitable treatment for lower limb skin defect with no surgical indications. Methods: From 2016.03 to 2017.03, 16 patients diagnosed as lower limb skin defect were included in the research. 8 patients were treated by platelet rich plasma, while 8patients received conservative treatment with recombinant human epidermal growth factor gel. Remove residual hemostatic gauze and dried blood every and change the new drug 7 days and observe the healing of the wound. Results: We observed that the scabby appeared in the skin defect, and there was no leakage in the wound in seventh day in all patients. The area was reduced about 1/4 in study group,1/6 in group in 7 days in control group. The control group were observed after 1 week, 1 case with infection, give again complementary makings bandage after debridement and using antibiotics. The area was reduced about 2/3 in experimental group, 1/4 in group in 14 days in control group. 3 weeks after treatment, the experimental group patients have been healed by more than 85% of the wound. With delayed 1-2 weeks after treatment all of the patients of this group had healing. Two patients in control group patients in the treatment of three weeks had more than 50% healing area who were continued to use this treatment method. The remaining 6 patients underwent surgical treatment(VSD) + skin graft/flap whose area reduced about 1/5. Comparing to the control group, the area of group A and B was significantly reduced(P <0.05). The area of study group was significantly reduced than the control groups(P < 0.05). Conclusions: The therapy of PRP can promote wound healing, shorten hospitalization time, reduce laid-in-bed complications, reduce the economic burden in the treatment of lower limb skin defect. [ABSTRACT FROM AUTHOR]

Objective: To investigate the clinical value and effect of spinal nerve medial branch ablation through transforaminal endoscopic in treatment of lumbar zygapophysial joint pain. Methods: From 2015.01 to 2017.01, 92 patients diagnosed as lumbar zygapophysial joint pain were included in the research. 36 patients were treated by spinal nerve medial branch ablation through transforaminal endoscopic, while 56 patients received conservative treatment. The visual analogue scale(VAS)and Japanese Orthopedics Association(JOA)scores before treatment, 1, 6 and 12 months after treatment were recorded and analyzed. The MacNab scores were recorded and analyzed 12 months after treatment. Results: The VAS and JOA scores of surgical treatment group showed significant improvement compared with that before operation(P<0.05), and there were no significant difference at each time point after surgery. The VAS and JOA scores of conservative treatment group in showed significant improved at 1 months after treatment compared with that before treatment(P<0.05), but there were no significant difference at each time after treatment compared with pretreatment. The VAS and JOA scores of surgical treatment group showed significant improvement compared with conservative treatment group at each time after treatment(P<0.05). The MacNab scores of surgical treatment group(94.44%)was significantly higher than that of conservative treatment group(33.33%). Conclusions: The spinal nerve branches ablation under transforaminal endoscopic is an effective and safe minimally invasive spine surgery technique with important clinical value in the treatment of lumbar zygapophysial joint pain. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)